Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Thursday 18 February, 2021

Omega Diagnostics Gp

Director/PDMR Shareholding

RNS Number : 5777P
Omega Diagnostics Group PLC
18 February 2021
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Director/PDMR Shareholding

Exercise of Options

and Total Voting Rights

 

18 February 2021

 

 

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has agreed to allot in total 450,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Third Unapproved Scheme by William Rhodes, Non-Executive Director of the Company, at a price of 15.25p per Ordinary Share.

 

Following this exercise Mr. Rhodes has today sold all 450,000 Ordinary Shares at a price of 91.115 pence per Ordinary Share. Following the above transactions Mr. Rhodes holds no Ordinary Shares but holds options over a further 1,380,406 Ordinary Shares.

 

Application will be made to the London Stock Exchange for the 450,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 25 February 2021.

 

Following Admission, the total number of Ordinary Shares in issue will be 182,208,167 and the total number of voting rights will therefore be 182,208,167. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 

Contacts: 

 

Omega Diagnostics Group PLC   

Tel: 01259 763 030

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

William Rhodes

2

Reason for notification

 

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN:  GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


15.25p

450,000

Purchase


91.115p

450,000

Sale


d.

Aggregated information

 

As above. 

 

e.

Date of the transaction

18 February 2021

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDDLSBDGBI

a d v e r t i s e m e n t